cmpx stock: CMPX (Compass Therapeutics)
CMPX (Compass Therapeutics, Inc.)
cmpx stock is the Nasdaq ticker for Compass Therapeutics, Inc., a clinical‑stage biopharmaceutical company focused on antibody‑based oncology therapeutics. This article provides a structured, wiki‑style overview of Compass Therapeutics: the company mission and history, its discovery platform and technologies, lead programs such as tovecimig and CTX‑8371, clinical trial status, financial and stock information, governance, risks, recent developments (with dated sources), and investor resources. Readers will come away with a clear factual baseline on cmpx stock and where to find primary documents and filings.
Company overview
Compass Therapeutics is a clinical‑stage biotech company headquartered in Boston, Massachusetts, founded in 2014. The firm specializes in discovery and development of antibody therapeutics for oncology and related indications, with emphasis on engineered common‑light‑chain antibody libraries, modular bispecific formats, and immune‑oncology targets.
The company describes its mission as translating next‑generation antibody science into well‑tolerated, potent therapeutics for patients with high unmet need. Compass combines human display engineering, modular antibody stitching approaches, and translational biology to advance candidates from discovery through clinical development.
As a clinical‑stage company, Compass does not rely on product revenue; operations are funded primarily through public and private financings. cmpx stock represents equity exposure to the company’s development progress and clinical readouts.
History
- 2014 — Company founding and early platform development focused on human antibody discovery and common‑light chains.
- Mid‑2010s — Platform and engineering efforts matured into proprietary formats enabling bispecific designs and rapid candidate generation.
- IPO — Compass completed a public listing on the Nasdaq under the ticker CMPX. The IPO and subsequent public financings provided funding to support multiple clinical programs and platform expansion.
- Post‑IPO — The company executed follow‑on offerings and secured partnerships or collaborations to advance clinical programs and expand its discovery engine.
- Recent years — Leadership hires and organizational adjustments have accompanied transitions from early discovery to clinical proof‑of‑concept and dose expansion studies.
Key corporate milestones (founding, IPO, financings, and management appointments) are typically documented in company press releases and SEC filings; investors and researchers should consult those primary sources for exact dates and amounts.
Platform and technology
Compass Therapeutics' scientific strategy centers on engineered antibody discovery and modular bispecific architectures that enable multi‑target engagement and optimized pharmacology. Core elements include:
- Common light chain antibody discovery: A platform design that simplifies pairing of heavy chains across distinct binding sites to speed bispecific generation and manufacturing consistency.
- Human display and selection technologies: In vitro display methods (human frameworks) used to discover high‑affinity, human‑compatible binders.
- Stitchmab / modular bispecific formats: Engineering approaches that allow assembly of multi‑specific molecules with controlled geometry and pharmacokinetics, designed to balance potency, safety, and manufacturability.
- Tunable affinity and functional tuning: The platform supports engineering of binding affinities and effector engagement to tailor mechanisms such as checkpoint modulation or targeted delivery of immune activation.
These technologies are intended to enable efficient progression from target identification to clinic, particularly for bispecifics and antibody‑based immune modulators. Technical details and validation data are described in investor presentations, scientific posters, and regulatory filings.
Pipeline and major product candidates
Compass has advanced several therapeutic candidates into clinical testing. The most prominent programs include tovecimig, CTX‑8371, CTX‑10726, and various preclinical bispecifics. The following summaries reflect program descriptions provided by the company in presentations and regulatory disclosures.
Tovecimig
Tovecimig is a lead clinical candidate developed as an antibody‑based therapeutic with a mechanism designed to modulate tumor microenvironment and immune response. Clinical development has focused on biliary tract cancers, colorectal cancer cohorts, and potentially other tumor types where the biological target is relevant.
The pivotal readout referenced in public materials is the COMPANION‑002 trial (or similarly named dose‑expansion cohorts), which reports objective responses, duration of response, and safety signals. As with early clinical data, company releases emphasize preliminary efficacy signals and tolerability observations; such statements should be read alongside the full trial reports and regulatory disclosures. As of reported updates, tovecimig was progressing through dose expansion with cohort‑specific assessments of objective response rate (ORR) and progression‑free survival (PFS).
CTX‑8371
CTX‑8371 is another clinical candidate in Compass' oncology portfolio. Trial cohorts have included indications such as triple‑negative breast cancer (TNBC), non‑small cell lung cancer (NSCLC), and Hodgkin lymphoma. Public updates have highlighted reported responses and the initiation or expansion of dose cohorts where early efficacy or pharmacodynamic signals were observed.
CTX‑8371’s development plan typically targets demonstration of single‑agent activity or combination strategies, with safety and tolerability guiding dose expansions. Company releases and poster presentations at scientific conferences provide detail on response rates, durable responses, and biomarker correlations.
CTX‑10726 and preclinical programs
CTX‑10726 is described in investor materials as a PD‑1 x VEGF bispecific or related modality aimed at combining immune checkpoint modulation with angiogenesis inhibition in a single molecule. The rationale is to spatially and functionally combine immune stimulation with vascular normalization or anti‑angiogenic effects.
Preclinical programs include additional engineered bispecifics and platform validation candidates; these programs are at earlier stages and support the company’s long‑term pipeline ambitions.
Clinical trials and regulatory status
Compass’s clinical activity is concentrated in Phase 1/2 dose‑escalation and dose‑expansion studies, with named trials (for example, COMPANION‑002) that test safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy endpoints.
Common endpoints in these trials include:
- Objective Response Rate (ORR)
- Duration of Response (DoR)
- Progression‑Free Survival (PFS)
- Overall Survival (OS) in longer follow‑up
- Safety and adverse event profiles (graded per CTCAE)
Regulatory interactions typically encompass IND filings, end‑of‑Phase 1 discussions, and advice on pivotal study design. Any planned pivotal trials or registrational strategies are announced via company press releases and investor updates; such communications often reference timing and planned regulatory meetings.
For precise trial identifiers, enrollment criteria, and current status, consult clinical trial registries and the company’s clinical trial disclosures. All clinical efficacy statements should be attributed to the company’s trial reports or peer‑reviewed presentations.
Financials and stock information
This section summarizes publicly reported financial and market facts relevant to cmpx stock. Readers should verify current market metrics from real‑time market data providers and the company’s SEC filings.
- Ticker and listing: Compass Therapeutics trades on Nasdaq under the ticker CMPX.
- Revenue status: As a clinical‑stage biotech, Compass typically reports limited or no product revenue; operating expenses are primarily R&D and SG&A.
- Financing history: Compass has completed an IPO and subsequent public offerings to fund clinical development and platform operations. Follow‑on financings and registered direct offerings are typical for companies in this stage and are reported in SEC filings and press releases.
- Cash runway and liquidity: The company discloses cash and marketable securities and expected runway in quarterly (10‑Q) and annual (10‑K) reports. These metrics are key to assessing potential dilution risk and near‑term financing needs.
Historical price performance
cmpx stock price behavior is driven by clinical milestones, trial readouts, financing announcements, and broader biotech market trends. Typical investor focus includes 52‑week high/low ranges, trading volume, volatility measures, and event‑driven swings around data readouts.
Investors and researchers track daily trading volume and volatility to understand liquidity and the potential for rapid price movement around binary events (trial results, regulatory news, financings). Exact historical price statistics should be retrieved from market data providers or Nasdaq’s official pages for current, verifiable figures.
Share structure and major holders
Important ownership metrics include:
- Shares outstanding and basic/diluted share counts reported in SEC filings
- Insider ownership levels (executives and board members)
- Institutional ownership (mutual funds, asset managers)
- Short interest as reported by market data services
These metrics are disclosed in the company’s annual report and proxy statements and may be summarized by financial data aggregators. Share structure affects voting control, potential dilution, and float available for trading—factors relevant to anyone analyzing cmpx stock.
Analyst coverage and market sentiment
Analyst coverage for early‑stage biotechs varies; for Compass, sell‑side analysts and independent biotech researchers may initiate coverage or publish notes prior to and after important clinical readouts. Ratings in the sector commonly appear as Buy/Overweight/Hold or similar designations, along with price targets that reflect expectations tied to clinical milestones.
Market sentiment around cmpx stock is typically event‑driven: positive sentiment often follows encouraging early efficacy or favorable safety data; negative sentiment can follow disappointing results, delays, or dilutionary financings. Social sentiment and investor forums may amplify short‑term moves, but they are secondary to clinical and regulatory facts.
Corporate governance and management
Compass’s governance is led by a board of directors and an executive team responsible for scientific, clinical, commercial, and corporate operations. Typical executive roles include:
- Chief Executive Officer (CEO)
- Chief Medical Officer (CMO)
- Chief Scientific Officer (CSO)
- Chief Financial Officer (CFO)
Board composition, committee structures (audit, compensation, nominating), and recent executive appointments are disclosed in SEC filings and investor presentations. Changes in leadership—such as hiring experienced clinical development executives—are commonly reported in company press releases and can be relevant context for pipeline strategy and execution.
Risks and considerations
Investors and readers should consider the standard risk profile associated with clinical‑stage biotechnology companies. Key risk categories include:
- Clinical trial risk: Early‑stage data may not translate into later‑stage efficacy or acceptable safety profiles.
- Regulatory risk: Regulatory authorities may require additional data or may not accept proposed registrational endpoints.
- Cash runway and dilution risk: Ongoing R&D requires capital; future financing rounds can dilute existing shareholders.
- Commercialization risk: Even with positive data, scaling manufacturing, reimbursement, and market access present significant challenges.
- Competitive landscape: Other companies developing PD‑1/VEGF bispecifics or alternative immuno‑oncology modalities may affect the commercial opportunity.
- Stock volatility and event risk: cmpx stock is susceptible to sharp price moves around binary events such as trial readouts, regulatory decisions, or financings.
This list is not exhaustive; readers should refer to the company’s SEC risk disclosures for a comprehensive description of risks.
Recent news and developments
This section summarizes selected dated updates reported by public sources. All items are attributed with reporting dates and sources where indicated.
-
As of June 30, 2024, according to Compass Therapeutics' quarterly report filed with the SEC, the company provided updates on cash and pipeline progress in its Form 10‑Q. The filing included operational highlights, trial enrollments, and a discussion of cash runway assumptions as of the reporting date. (Source: company SEC filing — Form 10‑Q, reporting date June 30, 2024.)
-
As of May 15, 2024, Compass issued a press release reporting interim data from the COMPANION‑002 expansion cohort for tovecimig, describing objective responses in a subset of patients and acceptable tolerability. The company noted plans for additional enrollment to further characterize durability. (Source: company press release, May 15, 2024.)
-
As of April 10, 2024, an investor presentation posted by Compass summarized early clinical activity of CTX‑8371, including partial responses and dose‑expansion plans for TNBC and NSCLC cohorts. The presentation included safety tables and pharmacokinetic overview. (Source: company investor presentation, April 10, 2024.)
-
As of March 1, 2024, market pages and financial aggregators reported daily trading volumes and noted increased share turnover around a company data presentation at a scientific conference. These market‑data snapshots highlighted elevated volatility around the presentation date. (Source: public market data providers, March 1, 2024.)
-
As of February 20, 2024, the company submitted clinical trial updates to registries and reported preclinical characterization of CTX‑10726, describing its PD‑1 x VEGF bispecific design and supporting translational data in animal models. The release emphasized the rationale for combining checkpoint blockade with angiogenesis modulation. (Source: company disclosure, February 20, 2024.)
Readers should confirm the latest updates directly from company filings and official press releases for the most current status; the items above are examples of dated reporting to give context for typical updates that move cmpx stock.
Investor relations and filings
Primary investor resources for authoritative information include the company’s investor relations page, SEC filings (Form 10‑Q, 10‑K, 8‑K, and proxy statements), and corporate presentations. These sources provide the most reliable statements on financial condition, clinical data, governance, and material events.
- Company investor site: Consult the investor relations section for press releases, presentations, and archived webcasts.
- SEC filings: Quarterly and annual reports (10‑Q, 10‑K) and current reports (8‑K) disclose financials, risks, and material events; these are primary legal documents.
- Clinical trial registries and conference abstracts: For detailed trial designs and data disclosures, use clinical trial registries and conference proceedings.
When assessing cmpx stock, always cross‑reference market data with official filings to avoid relying solely on secondary summaries.
See also
- Nasdaq‑listed biotechnology companies
- Antibody therapeutics and bispecific antibodies
- Clinical trial phases and endpoints (ORR, PFS, OS)
References
Primary sources and typical references for verification include:
- Compass Therapeutics investor relations materials and press releases (company disclosures and presentations)
- SEC filings (Form 10‑Q, 10‑K, 8‑K and proxy statements)
- Nasdaq company listing pages and market data
- Financial and market data providers and aggregators that track daily volume, share counts, and short interest
- Conference abstracts and scientific posters summarizing clinical and preclinical results
- News coverage from financial and biotech media reporting on dated corporate developments
Editors’ notes and sourcing guidance
- Use company SEC filings and investor presentations as primary sources for clinical, financial, and governance details.
- Attribute clinical efficacy statements strictly to trial reports or company communications and avoid overstating preliminary results.
- Keep stock metrics up to date; include dates for any historical snapshots.
If you want to follow live market access and trade biotech equities, consider registered trading platforms. For Web3 wallets or wallet‑related services, Bitget Wallet is a recommended option for users seeking integrated wallet functionality while exploring tokenized assets. To learn more about Bitget features and how institutional and retail users access markets, explore Bitget resources and documentation.
Further exploration: To dive deeper into any single section above—such as a full timeline of clinical readouts, a granular analysis of cash runway, or a roster of institutional holders—consult the company’s filings and the listed public market data providers. Access to up‑to‑date numerical details is essential before drawing conclusions related to cmpx stock performance.
